Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Ag-specific CD8+ CTL are crucial for effective tumor rejection. Attempts to treat human malignancies by adoptive transfer of tumor-reactive CTL have been limited due to the difficulty of generating and expanding autologous CTL with defined Ag specificity. The current study examined whether human CTL can be generated against the tumor-associated Ag HER2 using autologous dendritic cells (DC) that had been genetically engineered to express HER2. DC progenitors were expanded by culturing CD34+ hemopoietic progenitor cells in the presence of the designer cytokine HyperIL-6. Proliferating precursor cells were infected by a retroviral vector encoding the HER2 Ag and further differentiated into CD83+ DC expressing high levels of MHC, adhesion, and costimulatory molecules. Retroviral transduction of DC resulted in the expression of the HER2 molecule with a transduction efficiency of 15%. HER2-transduced DC correctly processed and presented the Ag, because HLA-A*0201-positive DC served as targets for CTL recognizing the HLA-A*0201-binding immunodominant peptide HER2(369-377). HER2-transduced DC were used as professional APCs for stimulating autologous T lymphocytes. Following repetitive stimulation, a HER2-specific, HLA-A*0201-restricted CTL line was generated that was capable of lysing HLA-A*0201-matched tumor cells overexpressing HER2. A CD8+ T cell clone could be generated that displayed the same specificity pattern as the parenteral CTL line. The ability to generate and expand HER2-specific, MHC class I-restricted CTL clones using HER2-transduced autologous DC in vitro facilitates the development of adoptive T cell transfer for patients with HER2-overexpressing tumors without the requirement of defining immunogenic peptides.
Meyer zum Büschenfelde
C
C
III Medizinische Klinik, Klinikum rechts der Isar, Technische Universität Müchen, Munich, Germany.
Nicklisch
N
N
Rose-John
S
S
Peschel
C
C
Bernhard
H
H
D017951:Antigen Presentation / Q000235:genetics; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism / Q000821:virology; D015703:Antigens, CD; D018952:Antigens, CD34 / Q000096:biosynthesis*; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D002455:Cell Division / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic / Q000235:genetics*; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D015789:HLA-A2 Antigen / Q000276:immunology / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology* / Q000821:virology; D006801:Humans; D007136:Immunoglobulins / Q000096:biosynthesis; D015850:Interleukin-6 / Q000502:physiology; D008213:Lymphocyte Activation / Q000235:genetics; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D010446:Peptide Fragments / Q000276:immunology / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D018123:Receptors, Interleukin / Q000502:physiology; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000494:pharmacology / Q000502:physiology; D012190:Retroviridae / Q000235:genetics* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured; D000097802:CD83 Antigen
D015703:Antigens, CD; D018952:Antigens, CD34; D015789:HLA-A2 Antigen; D007136:Immunoglobulins; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases; D018123:Receptors, Interleukin; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins; D000097802:CD83 Antigen; C104543:interleukin 6-interleukin 6 receptor fusion protein, recombinant